Leerink on Roivant Sciences (ROIV): 'We expect brepocitinib’s Ph2 cutaneous sarcoidosis (CS) trial to deliver compelling efficacy in 1H26'
Tweet Send to a Friend
Leerink Partners analyst David Risinger reiterated an Outperform rating and $32.00 price target on Roivant Sciences (NASDAQ: ROIV).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
